undamentalytics Newsletter
Sign in

Organigram Global Inc. (OGI) stock

Add to watchlist

Add holding +

NASDAQ: OGI Nasdaq Pharmaceuticals Next results ~December 15, 2026

C+ Fundamentals grade

Organigram Global Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Organigram Global Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds27 adding, 33 cuttingOf 7 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Organigram Global files

Where Organigram Global stands after its latest Filing

Revenue for the twelve months was $185m, up 57.8% on a year earlier, against a decline of 2.1% a quarter earlier. That growth ranks 9 of 74 among the pharmaceuticals companies we cover. Free-cash-flow margin rose to -9.5% from -51.0% a year earlier. Operating margin widened to -5.9% from -116.0%. The diluted share count is up 34.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 5 of our 7 financial-health checks.

Our model value for Organigram Global is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~December 15, 2026 (estimated)

Organigram Global Inc.'s trailing-twelve-month revenue grew 57.8% year on year, with a free-cash-flow margin of -9.5%. Where it stands out: long-term debt as % of assets of 0.0% ranks 1 of 53 pharmaceuticals companies we cover. Where it lags: change in share count of 34.0% ranks 57 of 62 pharmaceuticals companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 2688.4% while net income grew 47.0%: a 2735pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 57.8% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Growth speeding up. The growth rate is 59.9 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 15.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Loss-making. Operating margin is -5.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -9.5% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 34.0% in a year.
  • Below peers: gross margin. Gross margin of 34.8% ranks 46 of 59 pharmaceuticals companies we cover (median 59.8%).

Latest results

Earnings per share
$0.55 against an average estimate of -$0.00: beat by 23906.0%
Next report
December 15, 2026

Organigram Global's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.4%
  • 1 week+2.8%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$185M
Operating margin
-5.9%
Net margin
-9.6%
EPS (TTM, diluted)
$-0.14

Growth

Revenue growth
+57.8%
Change in growth rate
+59.9 pts
Share count change
+34.0%

Cash

Free cash flow (TTM)
-$17.6M
FCF margin
-9.5%
Stock pay % of revenue
1.6%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for OGI from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Organigram Global Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Organigram Global Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.86 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$6.9 ~$5.7–$8.4 Left out: out of range vs price (7.18x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Organigram Global Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: December 15, 2026, before the open.

Analysts' consensus

No analyst estimates are published for Organigram Global Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.00 $0.55 +23906.0%
Dec 2025 −$0.01 −$0.01 −79.4%
Sept 2025 −$0.01 −$0.20 −2827.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Nov 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Nov 20261315
  2. Oct 20261315
  3. Sep 20261315

Counts of recommendations published by analysts covering Organigram Global Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
—
of tradable shares
Days to cover
9.89
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
6%
of shares
Held by insiders
31.1%
of shares
Employees
1,139
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Organigram Global Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Organigram Global Inc.
$0 $50M $100M $150M $200M FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue (TTM), FY18 Q4: $9.7M Revenue (TTM), FY19 Q4: $60.7M Revenue (TTM), FY20 Q4: $64.5M Revenue (TTM), FY21 Q4: $62.5M Revenue (TTM), FY22 Q4: $114.7M Revenue (TTM), FY23 Q4: $120M Revenue (TTM), FY24 Q4: $117.5M Revenue (TTM), FY25 Q4: $185.4M $185.4M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY18 Q4 $9.7M
FY19 Q4 $60.7M
FY20 Q4 $64.5M
FY21 Q4 $62.5M
FY22 Q4 $114.7M
FY23 Q4 $120M
FY24 Q4 $117.5M
FY25 Q4 $185.4M
Revenue growth, TTM YoY Organigram Global Inc.
-200% 0% 200% 400% 600% FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue growth, TTM YoY, FY19 Q4: 523.6% Revenue growth, TTM YoY, FY20 Q4: 6.3% Revenue growth, TTM YoY, FY21 Q4: -3.2% Revenue growth, TTM YoY, FY22 Q4: 83.6% Revenue growth, TTM YoY, FY23 Q4: 4.6% Revenue growth, TTM YoY, FY24 Q4: -2.1% Revenue growth, TTM YoY, FY25 Q4: 57.8% 57.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY19 Q4 523.6%
FY20 Q4 6.3%
FY21 Q4 -3.2%
FY22 Q4 83.6%
FY23 Q4 4.6%
FY24 Q4 -2.1%
FY25 Q4 57.8%
Operating margin (TTM) Organigram Global Inc.
-200% 0% 200% 400% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Operating margin (TTM), FY18 Q4: 293.0% Operating margin (TTM), FY19 Q4: 6.8% Operating margin (TTM), FY20 Q4: -167.6% Operating margin (TTM), FY21 Q4: -116.0% Operating margin (TTM), FY22 Q4: -29.6% Operating margin (TTM), FY23 Q4: -162.7% Operating margin (TTM), FY24 Q4: -21.7% Operating margin (TTM), FY25 Q4: -5.9% -5.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY18 Q4 293.0%
FY19 Q4 6.8%
FY20 Q4 -167.6%
FY21 Q4 -116.0%
FY22 Q4 -29.6%
FY23 Q4 -162.7%
FY24 Q4 -21.7%
FY25 Q4 -5.9%
FCF margin (TTM) Organigram Global Inc.
-600% -400% -200% 0% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 FCF margin (TTM), FY18 Q4: -556.3% FCF margin (TTM), FY19 Q4: -178.9% FCF margin (TTM), FY20 Q4: -141.0% FCF margin (TTM), FY21 Q4: -51.0% FCF margin (TTM), FY22 Q4: -58.3% FCF margin (TTM), FY23 Q4: -42.0% FCF margin (TTM), FY24 Q4: -0.5% FCF margin (TTM), FY25 Q4: -9.5% -9.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY18 Q4 -556.3%
FY19 Q4 -178.9%
FY20 Q4 -141.0%
FY21 Q4 -51.0%
FY22 Q4 -58.3%
FY23 Q4 -42.0%
FY24 Q4 -0.5%
FY25 Q4 -9.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 40-F, 40-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Aug 2018 2019 Aug 2019 2020 Aug 2020 2021 Aug 2021 2022 Aug 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025
Income
Revenue 10 61 65 62 115 120 117 185
Gross profit 40 37 −42 −22 25 28 35 65
EBITDA 29 5 −107 −70 −30 −191 −23 −5
Operating income 29 4 −108 −72 −34 −195 −26 −11
Net income 16 −7 −101 −103 −11 −185 −33 −18
Diluted EPS $0.51 −$0.21 −$2.35 −$1.61 −$0.14 −$2.27 −$0.35 −$0.14
Growth (year on year)
Revenue — +523.6% +6.3% −3.2% +83.6% +4.6% −2.1% +57.8%
EBITDA — −83.9% <−999% — — — — —
Operating income — −85.5% <−999% — — — — —
Net income — −144.8% — — — — — —
Diluted EPS — −140.5% — — — — — —
Margins
Gross margin — 60.3% −65.1% −35.9% 21.7% 23.5% 29.7% 34.8%
EBITDA margin 297.1% 7.6% −165.9% −112.9% −26.0% −159.2% −19.3% −2.9%
Operating margin 293.0% 6.8% −167.6% −116.0% −29.6% −162.7% −21.7% −5.9%
Net margin 165.0% −11.9% −156.9% −165.1% −9.8% −153.8% −28.4% −9.6%
Free-cash-flow margin −556.3% −178.9% −141.0% −51.0% −58.3% −42.0% −0.5% −9.5%
Cash flow
Cash from operations −10 −26 −34 −23 −28 −29 3 −5
Capital spending 44 82 57 9 38 22 3 12
Free cash flow −54 −109 −91 −32 −67 −50 −1 −18
Stock-based pay 4 11 6 3 4 4 5 3
Free cash flow after stock pay −58 −120 −97 −35 −71 −55 −6 −21
Balance sheet
Cash — — — — — 38 98 60
Total debt 3 37 88 0 0 0 0 0
Net debt (negative = net cash) — — — — — −38 −98 −60
Diluted shares 32m 38m 45m 64m 77m 81m 95m 128m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 7 checks passed · September 30, 2025
What it owns · $404m
Short-term assets $205mLonger-term assets $199m
What it owes, and who funded it · $404m
Short-term liabilities $91mLonger-term liabilities $62mShareholders' equity $251m
  • Short-term assets cover short-term liabilities $205m of assets due within a year against $91m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $205m short-term assets against $62m of longer-dated liabilities.
  • More cash than debt $60m of cash against $17,951 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 35% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt −$5m of operating cash flow against $17,951 of debt.
  • Operating profit covers interest at least five times over Operating income of −$11m against $396,287 of interest.

From Organigram Global Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+34.0%
year over year
R&D spending
4.2%
of revenue
Days sales outstanding
92 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated OGI BTMD KMDA CRON AMRN HRTX Median
Revenue, last 12 months $185m $184m $180m $179m $176m $151m $276m
Revenue growth, last 12 months 57.8% −7.8% 12.1% 37.5% −22.3% 1.0% 9.9%
Revenue growth, 3-year average — 0.5% — 30.3% −18.3% 8.6% 5.5%
Revenue growth, latest quarter — −9.5% — 58.4% −20.4% 1.3% 6.5%
Gross margin 34.8% — 42.3% 45.9% 40.9% 70.1% 62.0%
Operating margin −5.9% 8.0% 14.5% −1.4% −18.2% −7.2% −5.9%
Operating margin, 3-year average — 13.9% 7.0% −38.9% −26.3% −13.5% −7.4%
Net margin −9.6% 3.2% 11.2% 39.1% −10.9% −22.5% −7.3%
Cash from operations / revenue −2.9% 13.3% 14.1% 33.5% 21.3% −7.7% 10.2%
Free-cash-flow margin −9.5% 10.8% 13.2% 27.8% 21.3% −8.0% 8.6%
Free-cash-flow margin, 3-year average — 13.2% 1.7% 11.1% 1.3% −47.0% 7.4%
Stock pay / revenue 1.6% 4.5% 0.5% 3.6% 4.2% 7.4% 3.6%
Change in share count 34.0% 3.3% 0.9% −2.1% 1.5% 5.9% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 57.8% 10.0% 8 of 74
Change in growth rate Growth +59.9pp -0.3pp 3 of 74
Gross margin Profitability 34.8% 59.8% 46 of 59
Operating margin Profitability -5.9% -5.9% 34 of 67
Net margin Profitability -9.6% -7.3% 41 of 75
Free-cash-flow margin Cash generation -9.5% 10.1% 53 of 74
Stock pay as % of revenue Cash generation 1.6% 3.6% 24 of 69
Long-term debt as % of assets Balance sheet 0.0% 23.8% 1 of 53
Change in share count Balance sheet 34.0% 1.5% 57 of 62
Days sales outstanding Balance sheet 92 days 72 days 41 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$7.9M
Institutions reporting
68
Shares held vs prior quarter
▼ 3.3%
Positions opened / closed
10 / 13

Top buyers and sellers, Q2 2026: 27 institutions bought and 33 sold ; the biggest buyer was UBS Group AG (+176K shares) and the biggest seller Lazard Asset Management LLC (−347K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Tidal Investments LLC $2.2M 2.2M 28.1% ▼ 0.2%
Renaissance Technologies LLC $1.5M 1.4M 18.7% ▼ 11.9%
Advisorshares Investments LLC $905,818 888K 11.5% ▼ 6.3%
Goldman Sachs Group Inc $623,709 611K 7.9% ▲ 7.0%
Morgan Stanley $314,270 308K 4.0% ▼ 15.4%
Baader Bank Aktiengesellschaft $254,455 250K 3.2% ▼ 4.9%
Bank Of Montreal $243,528 238K 3.1% ▲ 0.2%
Formidable Asset Management, LLC $214,817 160K 2.7% ▲ 2.3%
UBS Group AG $212,946 209K 2.7% ▲ 540.1%
Leonteq Securities AG $180,407 125K 2.3% ▼ 9.9%
Dimensional Fund Advisors LP $167,422 164K 2.1% ▼ 5.6%
Susquehanna International Group, LLP $156,677 154K 2.0% ▲ 40.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Organigram Global Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Organigram Global Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Organigram Global Inc. in brief

What does Organigram Global Inc. do?
Organigram Global Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in September.
What is Organigram Global Inc.'s stock ticker?
Organigram Global Inc. trades under the ticker OGI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Organigram Global Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Organigram Global Inc. reported revenue of $185M, 57.8% higher than a year earlier, according to its SEC filings.
What is Organigram Global Inc.'s free cash flow?
Organigram Global Inc.'s free-cash-flow margin is -9.5% of revenue over the trailing twelve months, ranking 53 of the 74 pharmaceuticals companies we cover.
Who are Organigram Global Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Tidal Investments LLC, Renaissance Technologies LLC and Advisorshares Investments LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
How much debt does Organigram Global Inc. have?
Organigram Global Inc.'s debt-to-equity ratio is 0.0%, from its latest balance sheet (34.6% five years earlier). The financial health section below sets out its other solvency checks.
Who are Organigram Global Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Organigram Global Inc. are Biote Corp., Kamada LTD, Cronos Group Inc., Amarin Corp plc\uk and Heron Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Organigram Global Inc.'s.
When is Organigram Global Inc.'s next earnings date?
Around December 15, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Organigram Global Inc. announces its own schedule.